

July 15, 2020

Listing Department

Code: **532 321**

BSE LIMITED

P J Towers, Dalal Street, Fort,
Mumbai – 400 001

Listing Department

Code: **CADILAHC**

NATIONAL STOCK EXCHANGE OF INDIA LIMITED

Exchange Plaza, Bandra Kurla Complex,
Bandra (E),
Mumbai – 400 051

Re.: Press Release

Dear Sir/Madam,

Please find enclosed a copy of press release dated July 15, 2020 titled “Zydus Cadila receives final approval from USFDA for Betamethasone Dipropionate Ointment”.

The contents of the press release give full details.

Please bring the aforesaid news to the notice of the members of the exchange and the investors’ at large.

Thanking you,

Yours faithfully,

For, **CADILA HEALTHCARE LIMITED**



DHAIVAL N. SONI
COMPANY SECRETARY



Encl.: As above

Zydus Cadila receives final approval from USFDA for Betamethasone Dipropionate Ointment

Ahmedabad, July 15, 2020

Zydus Cadila has received final approval from the USFDA to market Betamethasone Dipropionate Ointment USP, 0.05% (US RLD: Betamethasone Dipropionate Ointment).

Betamethasone Dipropionate Ointment is used to treat a variety of skin conditions (e.g., eczema, dermatitis, allergies, rash). The ointment will be manufactured at the group's Topical manufacturing facility at Ahmedabad.

The group now has 293 approvals and has so far filed over 390 ANDAs since the commencement of the filing process in FY 2003-04.

About Zydus Cadila

Zydus Cadila is an innovative, global pharmaceutical company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The group employs nearly 25000 people worldwide and is dedicated to creating healthier communities globally.
